Pharmacist-led review of empagliflozin and ertugliflozin following formulary update

CONCLUSIONS: Following the HNJH Medicaid HMO's coverage update from empagliflozin to ertugliflozin, some patients received inappropriate therapy and providers accepted clinical pharmacists' recommendations to optimize therapy.PMID:37616149 | DOI:10.37765/ajmc.2023.89408

Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: M Thomas Bateman Ryan Nguyen Ashwini B Navathe Caitlin McCarthy Source Type: research